

Cover Story
Capitol HillFree
By Matthew Bin Han Ong
Women who report sexual misconduct to NIH may find that their complaints have a limited shelf life—these complaints may become null, or at least ineligible for “even a cursory review” once perpetrators cut ties with NIH.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)















